Status:
COMPLETED
Efficacy and Safety of AAE581 in Postmenopausal Women With Osteopenia/Osteoporosis.
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Osteoporosis
Eligibility:
FEMALE
50-75 years
Phase:
PHASE2
Brief Summary
AAE581 is a specific inhibitor of the cysteine protease cathepsin K. This trial is designed to provide detailed information about the effects( efficacy and safety) of AAE581 on Bone Mineral Density.
Eligibility Criteria
Inclusion
- Low spine Bone Mineral Density
- 0 to 1 prevalent fracture in non lumber spine
Exclusion
- History or presence of any bone disease other than osteopenia /osteoporosis
- Previous treatment with other anti-osteoporosis agent(Wash out required)
- Evidence of vitamin D deficiency
- Other protocol-defined inclusion/exclusion criteria may apply.
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT00170911
Start Date
March 1 2005
Last Update
November 2 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.